On August 6, the U.S. Food and Drug Administration (FDA) approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections. Read more.

FDA approves new drug for skin infections

Genetic testing recommended for colorectal cancer patients

Dispelling pain myths

Special report – War on Pain: Resources for additional information

Special report – War on Pain: Multimodal and multidisciplinary therapy for pain management

Special report – War on Pain: Pain management across the military continuum

Special report – War on Pain: Understanding pain and pain mechanisms

CDC recognizes National Immunization Awareness Month

ANA Immunize resource

Study: Efforts to reduce smoking may reduce suicide

FDA approves new product to treat hereditary angioedema

FDA approves drug for treating rare type of non-Hodgkin lymphoma

FDA approves Afrezza

Lessons for more efficient research in healthcare settings

Study: Fecal microbiota transplant effective in immunocompromised patients

Bullying toolkit available

Study: Higher Hgb or receiving EPO doesn’t improve neuro outcomes in patients with TBI

Study: Nearly 80% of deaths in first three decades of life traced to unintentional injury or violence

International home care conference

What you can learn from failure

Achieving a work-life balance

Writing for good health

Nursing the dead: Medicolegal death scene investigation

Improving HCAHPS scores the old fashioned way

Key concepts in patient-centered care

Managing knee osteoarthritis in older adults

Health, safety, & wellness

Issues up close

Leadership insights

From the ANA CEO

An ending and a new beginning for American Nurse Today

Reducing sepsis deaths: A systems approach to early detection and management

July 2014 e-Edition

FDA approves new drug for serious skin infections

FDA approves new indication for imaging agent

New MRI technique may help in early diagnosis of Parkinson’s disease